PO.ET03.04 · 实验与分子治疗
胰腺癌细胞在营养受限和化疗应激下上调 NAD+ 生成
Pancreatic cancer cells elevate NAD+production in response to nutrient limitation and chemotherapeutic stress
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:胰腺癌(PC)细胞持续处于非整倍体、营养缺乏和缺氧诱导的应激状态,这可能需要升高的 NAD+ 水平以维持关键的生存功能,如抗氧化防御、线粒体活性和 DNA 修复。因此,我们假设 PC 细胞通过升高 NAD+ 水平来适应其微环境中的化疗和营养剥夺。
方法:我们使用液相色谱-质谱(LC-MS)测定应激(营养剥夺和化疗)下癌细胞与非癌细胞中的 NAD+ 及其前体。使用 Western blot 和 qPCR 评估化疗后 NAD+ 合成通路中酶的表达。分别向无胸腺裸鼠和 C57BL/6 小鼠注射 MIA PaCa-2。一旦形成可触及的肿瘤,小鼠接受溶媒或奥沙利铂(5 mg/kg,每周给药两次)治疗,持续 21 天,然后收集肿瘤并检测 NAD+ 及其前体。
结果:与非癌细胞(HPDE 和 HPNE)相比,PC 细胞(PANC-1、MIA PaCa-2 和 BxPC-3)的基线细胞内 NAD+ 和 NAM 水平更高,并在完全培养基处理 72 小时后仍保持升高。在细胞应激增加(如葡萄糖限制)时,MIA PaCa-2 细胞中 NAD+ 和 NAM 水平的升高比 HPNE 细胞更显著,表明胰腺癌细胞能够适应因葡萄糖撤除引起的氧化和能量应激所需的 NAD+ 需求增加。在四天的生长过程中,PANC-1 和 MIA PaCa-2 细胞的细胞内 NAD+ 水平始终高于 HPNE 细胞。有趣的是,无论葡萄糖水平如何,所有细胞系培养基中的 NAM 浓度在 72 小时内下降约 40%,表明对外源 NAD+ 前体的强烈利用。奥沙利铂和 5-氟尿嘧啶(5FU)均显著提高了 MIA PaCa-2 和 PANC-1 细胞中的 NAD+ 和 NAM 水平,支持了 NAD+ 是应激下驱动生存机制所必需的这一模型。奥沙利铂处理提高了 NMNAT1 的 mRNA 水平以及 NAPRT、NRK 和 NMNAT1(Preiss-Handler 和 NAD+ 补救通路中的主要酶)的蛋白水平。尽管化疗未改变细胞内 NAMPT(iNAMPT)的 mRNA 水平,但提高了 iNAMPT 蛋白水平,而细胞外 NAMPT(eNAMPT)蛋白水平保持不变。化疗还在体内 MIA PaCa-2 和 KPC 小鼠异种移植模型中提高了 NAD+ 水平。
结论:这些发现表明,PC 细胞主动优先进行 NAD+ 合成,作为在恶劣微环境中生存并发展化疗耐药的适应性机制。因此,靶向 NAD+ 合成通路提供了一个可增强胰腺癌化疗敏感性的治疗脆弱点。
查看英文原文 English abstract
Introduction: Pancreatic cancer (PC) cells are consistently in a state of aneuploidy, nutrient deficiency, and hypoxia-induced stress, which may necessitate increased NAD + levels to maintain critical survival functions such as antioxidant defense, mitochondrial activity, and DNA repair. Therefore, we hypothesized that PC cells adapt to chemotherapy and nutrient deprivation in their microenvironment by elevating NAD+ levels.
Methods: We used liquid chromatography-mass spectrometry (LC-MS) to measure NAD + and its precursors in cancer versus non-cancer cells under stress (nutrient deprivation and chemotherapy). Western blot and qPCR were used to assess enzyme expression in NAD+ synthesis pathways following chemotherapy. Athymic nude mice and C57BL/6 mice were injected with MIA PaCa-2, respectively. Once palpable tumors formed, the mice received treatments with either vehicle or oxaliplatin (5 mg/kg, administered twice weekly) for 21 days, and tumors were collected and tested for NAD+ and its precursors.
Results: Baseline intracellular NAD + and NAM levels were higher in PC cells (PANC-1, MIA PaCa-2, and BxPC-3) compared to non-cancer cells (HPDE and HPNE) and stayed elevated after 72 hours of treatment with complete media. During increased cellular stress, such as glucose limitation, NAD + and NAM levels rose more significantly in MIA PaCa-2 cells than in HPNE cells, demonstrating pancreatic cancer cells' ability to adapt to the increased NAD + demand required to counteract oxidative and energy stress caused by glucose withdrawal. Intracellular NAD + levels consistently remained higher in PANC-1 and MIA PaCa-2 cells than in HPNE cells during four days of growth. Interestingly, NAM concentrations in the media declined by ~ 40% over 72 hours across all cell lines, regardless of glucose level, indicating strong utilization of external NAD+ precursors. Both Oxaliplatin and 5-fluorouracil (5FU) significantly increased NAD + and NAM levels in MIA PaCa-2 and PANC-1 cells, supporting the model that NAD + is necessary for fueling survival mechanisms under stress. Oxaliplatin treatment increased mRNA levels of NMNAT1 and protein levels of NAPRT, NRK, and NMNAT1, the main enzymes in the Preiss-Handler and NAD + salvage pathways. Although chemotherapy did not change intracellular NAMPT (iNAMPT) mRNA levels, it increased iNAMPT protein levels, whereas extracellular NAMPT (eNAMPT) protein levels remained unchanged. Chemotherapy also increased NAD+ levels in both MIA PaCa-2 and KPC mouse xenograft models in vivo.
Conclusion: These findings suggest that PC cells actively prioritize NAD + synthesis as an adaptive mechanism to survive the harsh microenvironment and develop chemoresistance. Therefore, targeting NAD+ synthesis pathways offers a therapeutic vulnerability to enhance chemotherapy susceptibility in pancreatic cancer.
利益披露 Disclosure
F. Nakazzi, None..
M. Zarei, None..
M. Lopes, None..
H. J. Graor, None..
W. C. Beegan, None..
E. Gu, None..
S. Rezaei, None..
P. J. Lund, None.